918136-59-1

Upstream product

• 918136-57-9 2-bromo-4-chloro-6-methoxy-3-methyl-phenylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 918136-58-0 N,N-di(tert-butyloxycarbonyl)-2-bromo-4-chloro-6-methoxy-3-methyl-phenylamine 

Downstream Products

• 918136-60-4 6-chloro-8-methoxy-4,5-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 

Relevant academic research and scientific papers

Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: Structure-activity relationship elucidation

The optimisation of affinity and selectivity in a novel series of dual 5-HT5A/5-HT7 receptor ligands is described. Brain penetrant 2-aminodihydroquinazolines with low nanomolar affinities were identified.

8-Alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines

The present invention relates to compounds of formula wherein R1, R2, R3, and n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome.